The Technical AnalystExchange: HKSE Sector: Biotechnology Industry: Biotechnology
Essex Bio-Technology Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.42% HKD2.39
America/New_York / 3 mai 2024 @ 04:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 356.42 mill |
| EPS: | 0.470 |
| P/E: | 5.09 |
| Earnings Date: | Mar 18, 2024 |
| SharesOutstanding: | 567.54 mill |
| Avg Daily Volume: | 0.124 mill |
| RATING 2024-05-02 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.54x |
| Company: PE 5.09 | sector: PE 9.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.14x |
| Company: PE 5.09 | industry: PE 35.62 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD7.07 (195.65%) HKD4.68 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 2.31 - 2.45 ( +/- 3.11%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | HKD2.39 (0.42% ) |
| Volume | 0.147 mill |
| Avg. Vol. | 0.124 mill |
| % of Avg. Vol | 118.45 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 1061.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
1061.HK
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.